4D Molecular Therapeutics Inc
(FDMT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 37 | 20,723 | 3,129 | 18,038 | 13,612 |
| Gross Profit | 37 | 20,723 | 3,129 | 18,038 | 13,612 |
| Operating Expenses | 187,878 | 133,590 | 113,161 | 89,371 | 70,276 |
| Operating Income | -187,841 | -112,867 | -110,032 | -71,333 | -56,664 |
| Other Income | 26,973 | 12,030 | 2,538 | 16 | -29 |
| Pre-tax Income | -160,868 | -100,837 | -107,494 | -71,317 | -56,693 |
| Net Income Continuous | -160,868 | -100,837 | -107,494 | -71,317 | -56,693 |
| Net Income | $-160,868 | $-100,837 | $-107,494 | $-71,317 | $-56,693 |
| EPS Basic Total Ops | -2.98 | -2.58 | -3.32 | -2.57 | -8.82 |
| EPS Basic Continuous Ops | -2.98 | -2.58 | -3.32 | -2.57 | -8.82 |
| EPS Diluted Total Ops | -2.98 | -2.58 | -3.32 | -2.57 | -8.82 |
| EPS Diluted Continuous Ops | -2.98 | -2.58 | -3.32 | -2.57 | -8.82 |
| EPS Diluted Before Non-Recurring Items | -2.98 | -2.58 | -3.32 | -2.57 | -8.82 |
| EBITDA(a) | $-190,370 | $-109,907 | $-106,570 | $-69,091 | $-55,221 |